A prior study found that MYC upregulates tumor cell PD-L1, a cell surface molecule that dampens the adaptive immune response, in a mouse model of MYC-driven lymphoma27, suggesting blocking PD-L1 therapy might be effective in MYC-driven cancers. This evidence concerns the gene CD274 and neoplasm.